The case for SABR as the global standard for non-operable early-stage non-small cell lung cancer
Lancet Reg Health Am
.
2022 Aug 26:14:100361.
doi: 10.1016/j.lana.2022.100361.
eCollection 2022 Oct.
Authors
Adam Mutsaers
1
,
Alexander V Louie
1
,
Fabio Ynoe Moraes
2
Affiliations
1
Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario M4N 3M5, Canada.
2
Division of Radiation Oncology, Department of Oncology, Kingston General Hospital, Queen's University, Kingston, Ontario, Canada.
PMID:
36777385
PMCID:
PMC9903782
DOI:
10.1016/j.lana.2022.100361
No abstract available